MYOCD and cardiac hypertrophy: Our data document for the first time, the upregulation of cardiac MYOCD in cardio- renal patients and cardiac-specific MYOCD silencing in a cardiorenal model has an integrated beneficiary effect on cardiac hypertrophy, fibrosis and function.